STOCK TITAN

Argen X SE - ARGX STOCK NEWS

Welcome to our dedicated news page for Argen X SE (Ticker: ARGX), a resource for investors and traders seeking the latest updates and insights on Argen X SE.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Argen X SE's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Argen X SE's position in the market.

Rhea-AI Summary
argenx presents data showcasing the transformative outcomes of VYVGART and VYVGART Hytrulo for patients with autoimmune diseases. The Phase 3 ADHERE trial data for CIDP patients and real-world evidence for gMG patients demonstrate significant improvements and reduced steroid use. The results highlight rapid, deep, and durable functional improvements in CIDP patients, with a high rate of treatment continuation. The FDA decision on CIDP sBLA for VYVGART Hytrulo is expected by June 21, 2024. The AAN presentations emphasize the ability of VYVGART and VYVGART Hytrulo to drive rapid, deep, and sustained improvements in gMG patients, reducing the burden of long-term steroid use.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
none
-
Rhea-AI Summary
argenx SE announces the continuation of efgartigimod development to Phase 3 in primary Sjogren’s disease based on positive Phase 2 RHO study results. The study showed a favorable safety profile and consistent efficacy across multiple endpoints, supporting proof-of-concept. The decision is backed by promising biomarker data, indicating a potential alternative treatment for patients with unmet medical needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
-
Rhea-AI Summary
argenx SE announces the Annual General Meeting of shareholders to be held on May 7, 2024, at Hilton Amsterdam Schiphol. The agenda includes appointments of directors, remuneration policies, and financial auditors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
none
Rhea-AI Summary
argenx SE receives regulatory approval in Japan for VYVGART® to treat primary immune thrombocytopenia (ITP), marking the first global approval for this indication. The approval is based on positive Phase 3 trial results showing efficacy in chronic ITP patients. VYVGART has a well-tolerated safety profile and demonstrated a rapid onset of effect, offering a precision intervention for ITP patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
none
-
Rhea-AI Summary
argenx SE announces data presentation highlighting potential innovation for CIDP patients with VYVGART and VYVGART Hytrulo at AAN Annual Meeting. Positive results from the ADHERE study submitted to the FDA for potential approval of VYVGART Hytrulo in CIDP. Clinical data demonstrates consistent efficacy, safety, and cost-effectiveness of VYVGART in treating gMG patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
none
-
Rhea-AI Summary
argenx SE reported $374 million in fourth-quarter and $1.2 billion in full-year global net product sales, with sBLA for VYVGART Hytrulo for CIDP accepted for priority review by FDA. The company plans to report data from six Phase 2 proof-of-concept trials by the end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.45%
Tags
Rhea-AI Summary
argenx, a global immunology company, will participate in investor conferences in March 2024 to discuss their commitment to improving the lives of people with severe autoimmune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
conferences
-
Rhea-AI Summary
argenx schedules conference call to discuss full year 2023 financial results and fourth quarter business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
conferences earnings
-
Rhea-AI Summary
argenx SE announces FDA acceptance of sBLA for VYVGART Hytrulo for CIDP treatment with a PDUFA target action date of June 21, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
Rhea-AI Summary
argenx SE announces the approval of VYVDURA for subcutaneous use in Japan, providing more treatment options for adult patients with generalized myasthenia gravis (gMG) who do not respond to other therapies. This approval follows positive results from the Phase 3 ADAPT-SC study, demonstrating comparable efficacy to VYVGART IV.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
none
Argen X SE

Nasdaq:ARGX

ARGX Rankings

ARGX Stock Data

22.63B
58.81M
0%
55.84%
2.03%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Netherlands
Breda

About ARGX

Argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.